Premium
MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS
Author(s) -
Frustaci A. M.,
Tedeschi A.,
Zinzani P. L.,
Pietrasanta D.,
Coscia M.,
Zenz T.,
Motta M.,
Gaidano G.,
Scarfò L.,
Deodato M.,
Zamprogna G.,
Vitale C.,
Cairoli R.,
Rossi D.,
Montillo M.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.40_2880
Subject(s) - medicine , obinutuzumab , venetoclax , atezolizumab , adverse effect , neutropenia , rituximab , febrile neutropenia , bendamustine , oncology , chronic lymphocytic leukemia , lymphoma , toxicity , leukemia , cancer , pembrolizumab , immunotherapy
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom